Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
暂无分享,去创建一个
L. Dogliotti | D. Fontana | E. Bollito | A. Berruti | A. Mosca | A. Angeli | G. Gorzegno | R. Tarabuzzi | M. Poggio | M. Torta | M. Mari | Dario Fontana
[1] P. Abrahamsson. Neuroendocrine differentiation in prostatic carcinoma , 1999, The Prostate.
[2] K. Akakura. [Serum chromogranin A in prostate cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.
[3] L. Dogliotti,et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] S. Cappia,et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] R. Montironi,et al. Vascular endothelial growth factor expression and capillary architecture in high‐grade PIN and prostate cancer in untreated and androgen‐ablated patients , 2000, The Prostate.
[6] J. Baniel,et al. Low PSA Metastatic Androgen– Independent Prostate Cancer , 2000, European Urology.
[7] L. Dogliotti,et al. Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.
[8] T. Kwast,et al. Androgen Deprivation of the Prohormone Convertase-310 Human Prostate Cancer Model System Induces Neuroendocrine Differentiation , 2000 .
[9] H. Fuse,et al. Effect of chromogranin A (pancreastatin) fragment on invasion of prostate cancer cells. , 1999, Cancer letters.
[10] M. Tarle. Serum chromogranin A in monitoring metastatic prostate cancer patients. , 1999, Anticancer research.
[11] E. Caporossi,et al. [Serum chromogranin A in prostate cancer. Preliminary results]. , 1999, Minerva medica.
[12] K. Tsao,et al. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy , 1999, Journal of clinical laboratory analysis.
[13] H. Bonkhoff,et al. Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MIB-1), and phenotype markers in routinely processed tissue sections , 1999, Virchows Archiv.
[14] G. Pruneri,et al. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy , 1998, The Prostate.
[15] O. Cussenot,et al. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors , 1998, The Prostate. Supplement.
[16] L. Bégin,et al. Neuroendocrine differentiation and the bombesin/gastrin‐releasing peptide family of neuropeptides in the progression of human prostate cancer , 1998, The Prostate. Supplement.
[17] H. Bonkhoff. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status , 1998, The Prostate. Supplement.
[18] M. Astill,et al. Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients , 1998, Journal of clinical laboratory analysis.
[19] K. Öberg,et al. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] J. Laissue,et al. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. , 1997, The Yale journal of biology and medicine.
[21] M. Salvatore,et al. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. , 1997, The Journal of clinical endocrinology and metabolism.
[22] O. Haugen,et al. Use of neuroendocrine serum markers in the follow‐up of patients with cancer of the prostate , 1997, The Prostate.
[23] S. Takeha,et al. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. , 1997, The Journal of urology.
[24] M. Stridsberg,et al. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? , 1997, The Prostate.
[25] R. Jian,et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. , 1996, Gut.
[26] P. di Sant'Agnese,et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.
[27] O. Cussenot,et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. , 1996, The Journal of urology.
[28] A. Corti,et al. Characterisation of circulating chromogranin A in human cancer patients. , 1996, British Journal of Cancer.
[29] S. Lamberts,et al. Drug therapy : octreotide , 1996 .
[30] V. Mazzaferro,et al. The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. , 1996, Digestion.
[31] S. Nilsson,et al. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. , 1995, Cancer research.
[32] C. Logothetis,et al. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. , 1995, Urologic oncology.
[33] T. H. van der Kwast,et al. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long‐term follow‐up study with patients treated by radical prostatectomy , 1995, International journal of cancer.
[34] P. di Sant'Agnese,et al. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. , 1994, The Journal of urology.
[35] P. A. Sant'agnese,et al. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. , 1992 .
[36] P. di Sant'Agnese,et al. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications , 1992, Cancer.
[37] P. Scardino,et al. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. , 1991, The Journal of urology.
[38] R. Cohen,et al. Prostatic carcinoma: histological and immunohistological factors affecting prognosis. , 1990, British journal of urology.
[39] J. Oesterling,et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.
[40] L. Grimelius,et al. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". , 1989, Pathology, research and practice.
[41] L. Grimelius,et al. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. , 1987, Pathology, research and practice.
[42] M. Dauge,et al. A.P.U.D. type endocrine tumour of the prostate. Incidence and prognosis in association with adenocarcinoma. , 1987, Progress in clinical and biological research.
[43] Shinichiro,et al. Carcinoma , 1906, The Hospital.